ER+ Breast Cancer Pipeline Offers Novel Therapeutic Targets For The Treatment Of Breast Cancer

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis

As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample

Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.